Miragen Therapeutics Inc (NASDAQ:MGEN) Receives $15.17 Average Price Target from Analysts
Miragen Therapeutics Inc (NASDAQ:MGEN) has been assigned an average rating of “Buy” from the six research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $15.17.
MGEN has been the topic of several recent analyst reports. ValuEngine raised shares of Miragen Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright initiated coverage on shares of Miragen Therapeutics in a research note on Monday, August 19th. They set a “buy” rating and a $3.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Miragen Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 9th.
Large investors have recently made changes to their positions in the business. A.R.T. Advisors LLC acquired a new position in shares of Miragen Therapeutics in the second quarter worth $28,000. Citadel Advisors LLC acquired a new position in shares of Miragen Therapeutics in the second quarter worth $57,000. Invesco Ltd. acquired a new position in shares of Miragen Therapeutics in the second quarter worth $71,000. Jane Street Group LLC acquired a new position in shares of Miragen Therapeutics in the second quarter worth $159,000. Finally, Paloma Partners Management Co acquired a new position in shares of Miragen Therapeutics in the second quarter worth $239,000. 39.24% of the stock is currently owned by institutional investors.
Miragen Therapeutics (NASDAQ:MGEN) last announced its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. Miragen Therapeutics had a negative return on equity of 85.50% and a negative net margin of 925.52%. The company had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.89 million. As a group, analysts expect that Miragen Therapeutics will post -1.15 EPS for the current year.
Miragen Therapeutics Company Profile
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Featured Story: What is a management fee?
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.